SCHEMBL16629832

SCHEMBL16629832

CNCc1nc2ccccc2c(=O)n1C

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC6 Q9UBN7 2/20 0.61
HDAC8 Q9BY41 1/20 0.59
ACKR3 P25106 4/20 0.56
KDM4E B2RXH2 3/20 0.55
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
TDP1 Q9NUW8 2/20 0.54
ALOX15 P16050 1/20 0.54
TSHR P16473 1/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
PDE10A Q9Y233 1/20 0.53
POLB P06746 1/20 0.51
NPSR1 Q6W5P4 1/20 0.49
LMNA P02545 1/20 0.49
USP2 O75604 1/20 0.49
NPC1 O15118 2/20 0.49
RAB9A P51151 2/20 0.49
CYP1A2 P05177 1/20 0.48
CYP3A4 P08684 1/20 0.48
CYP2D6 P10635 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3818640 0.82 HDAC6 (0.66) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL28658140 0.81 TDP1 (0.62) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL29571733 0.81 HDAC6 (0.64) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL1161498 0.81 HDAC6 (0.64) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL17088213 0.81 HDAC6 (0.68) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL18017411 0.79 HDAC6 (0.71) HDAC6HDAC8KDM4EALDH1A1MAPT
SCHEMBL5772949 0.78 HDAC6 (0.69) HDAC6HDAC8KDM4EALDH1A1MAPT
SCHEMBL5739868 0.78 HDAC6 (0.69) HDAC6HDAC8ACKR3KDM4EALDH1A1
SCHEMBL28004438 0.78 KDM4E (0.65) HDAC6HDAC8ACKR3KDM4EALDH1A1
Hydrochloric Acid SCHEMBL31505010 0.77 HDAC6 (0.50) HDAC6HDAC8ACKR3KDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3052099-B1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME (US) 2019-08-21 EP disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-9486448-B2 Pyrrolidine derived beta 3 adrenergic receptor agonists MERCK SHARP & DOHME CORP. (US) 2016-11-08 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2016-08-18 US disclosed
WO-2015050798-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS MERCK SHARP & DOHME CORP. (US) 2015-04-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160235727-A1 NOVEL PYRROLIDINE DERIVED BETA 3 ADRENERGIC RECEPTOR AGONISTS ADRB3, ADRB1, ADRB2 HDAC6 2043/4885HDAC8 4076/4885ACKR3 163/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.